OCUL · XBRL financial data

Ocular Therapeutix financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OCUL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	17	44	51	58	64	52
Cost of goods and services sold	2	4	5	5	6	7
Research and development	29	50	53	61	128	197
General and administrative	23	32	32	34	61	64
Operating income (loss)	(63)	(78)	(79)	(82)	(172)	(270)
Interest expense	7	7	7	11	14	12
Other income (expense)	—	0	(0)	(0)	—	—
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(156)	(7)	(71)	(81)	(194)	(266)
Earnings per share, basic USD per share	(2.56)	(0.09)	(0.92)	(1.01)	(1.22)	(1.42)
Earnings per share, diluted USD per share	(2.56)	(0.98)	(0.97)	(1.02)	(1.22)	(1.42)
Weighted average shares, basic millions of shares	61	76	77	80	158	187
Weighted average shares, diluted millions of shares	61	82	83	86	158	187

Fiscal years (OCUL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	228	164	102	196	392	737
Accounts receivable	12	21	21	26	32	31
Inventory	1	1	2	2	3	4
Prepaid and other current assets	5	5	4	8	13	11
Total current assets	246	191	130	232	441	782
Property and equipment, net	8	7	10	12	9	20
Right-of-use asset	6	5	8	6	6	5
Total assets	262	205	149	252	458	808
Accounts payable	3	5	5	4	4	4
Accrued liabilities	14	20	24	29	35	44
Total current liabilities	27	26	31	35	41	51
Lease liability, non-current	8	6	9	7	5	3
Total liabilities	186	117	114	161	143	154
Accumulated deficit	(539)	(546)	(617)	(698)	(891)	(1,157)
Total stockholders' equity	76	88	35	91	315	654
Total liabilities and equity	262	205	149	252	458	808
Common shares outstanding (cover page) millions of shares	76	77	78	149	159	218

Fiscal years (OCUL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(156)	(7)	(71)	(81)	(194)	(266)
Stock-based compensation	8	15	17	18	33	43
Depreciation and amortization	3	2	2	3	4	4
Net cash from operating activities	(54)	(66)	(60)	(70)	(135)	(205)
Purchases of property and equipment	1	1	4	6	1	12
Net cash from investing activities	(1)	(1)	(4)	(6)	(1)	(12)
Proceeds from issuing common stock	225	—	—	117	—	—
Proceeds from long-term debt	—	—	—	82	—	—
Repayments of long-term debt	—	—	—	26	—	—
Net cash from financing activities	228	3	1	170	332	562
Net change in cash	174	(64)	(62)	94	196	345

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Merus	367	12	(85)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.